These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37787009)

  • 41. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.
    Spaan M; Carey I; Bruce M; Shang D; Horner M; Dusheiko G; Agarwal K
    J Hepatol; 2020 Jun; 72(6):1097-1104. PubMed ID: 31981726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients].
    Cao ZH; Ma LN; Liu YL; Jin Y; He ZM; Lu JF; Zhang YH; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):498-501. PubMed ID: 24074706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
    Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
    Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study.
    Lian J; Kuang W; Jia H; Lu Y; Zhang X; Ye C; Gu J; Lv Y; Yu J; Zhang Y; Lu X; Zhao Y; Yang D; Wang K; Zhao P; Yu Y; Bai L; Zhang J; Zhang X; Yang Y
    J Med Virol; 2022 Nov; 94(11):5475-5483. PubMed ID: 35836102
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
    Gurusamy KS; Tsochatzis E; Toon CD; Xirouchakis E; Burroughs AK; Davidson BR
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006803. PubMed ID: 24307460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone.
    Lin S; Fu Y; Wu W; Chen T; Chen N; Xun Z; Liu C; Ou Q; Zeng Y; Huang H
    Int J Med Sci; 2020; 17(10):1458-1463. PubMed ID: 32624702
    [No Abstract]   [Full Text] [Related]  

  • 49. Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy.
    Hercun J; Kim GE; Da BL; Rotman Y; Kleiner DE; Chang R; Glenn JS; Hoofnagle JH; Koh C; Heller T
    Aliment Pharmacol Ther; 2021 Jul; 54(2):176-182. PubMed ID: 34048594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
    Gardner S; Cutrell A; Elko-Simms C; Adkison K; Hamatake R; Walker J; Rodriguez-Torres M; Hong Z
    Liver Int; 2014 Jul; 34(6):e89-95. PubMed ID: 24107072
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
    Markova AA; Mihm U; Schlaphoff V; Lunemann S; Filmann N; Bremer B; Berg T; Sarrazin C; Zeuzem S; Manns MP; Cornberg M; Herrmann E; Wedemeyer H
    PLoS One; 2014; 9(4):e94512. PubMed ID: 24751903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
    Li J; Qu L; Sun X; Liu Y; Gong Q; Yu D; Zhang D; Jiang J; Chen J; Wei D; Han Y; Gao Y; Zhang Q; She W; Chen L; Zhang J; Zhang X
    J Viral Hepat; 2021 Oct; 28(10):1381-1391. PubMed ID: 34228855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis.
    Tugui L; Dumitru M; Iacob S; Gheorghe L; Preda C; Dinu I; Becheanu G; Dumbrava M; Nicolae I; Andrei A; Lupu A; Diculescu M
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):368-75. PubMed ID: 25076702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients.
    Erken R; Loukachov VV; de Niet A; Jansen L; Stelma F; Helder JT; Peters MW; Zaaijer HL; Kootstra NA; Willemse SB; Reesink HW
    J Clin Exp Hepatol; 2022; 12(3):735-744. PubMed ID: 35677522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: a multicenter Romanian trial.
    Gheorghe L; Iacob S; Simionov I; Vadan R; Constantinescu I; Caruntu F; Sporea I; Grigorescu M
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):377-82. PubMed ID: 22187703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long term efficacy of pegylated ınterferone in the treatment of delta hepatitis: a single center experience.
    Kılıç ZM; Köksal AS; Kalkan IH; Suna N; Yıldız H; Kacar S
    Acta Gastroenterol Belg; 2016; 79(2):329-335. PubMed ID: 27821029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis.
    Abdrakhman A; Ashimkhanova A; Almawi WY
    Antiviral Res; 2021 Jan; 185():104995. PubMed ID: 33321155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.